Mexico, Colombia and Cuba Formalize Talks On New Latin American Regulator

Medicines regulators from Mexico, Colombia and Cuba have pledged to create a new agency for medicines and medical devices of Latin America and the Caribbean.

collaboration
Latin American Regulators Commit To Creating New Regional Agency • Source: Shutterstock

Cofepris, Invima and Cecmed, the medicine regulators in Mexico, Colombia and Cuba respectively, have signed a declaration to formalize talks on creating a new regional medicines regulator for Latin America and the Caribbean. The Acapulco Declaration represents a “major milestone” in the journey to establish the agency, make the region more self-sufficient in health care and bring safe, effective and quality medicines more swiftly to patients, said Alejandro Svarch Pérez, director of Cofepris.

The declaration was signed in Acapulco, Mexico, on 26 April and follows proposals made earlier this year on creating a new regulator that would work towards achieving: regulatory convergence and mutual recognition, stimulating R&D; support local production; and exploring procurement mechanisms to guarantee sustainable access and financing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Latin America

More from Geography

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.